Data from Pfizer's coronavirus vaccine trials in children aged 2 years and older could be available as early as this fall, Pfizer's Senior Vice President of Vaccine Clinical Research and Development Dr. William Gruber said, possibly paving the way for use before the end of 2022. The drugmaker is also conducting clinical trials on their vaccine for babies aged 6 months and older.